Completed PHASE1 INTERVENTIONAL 2-arm NCT01297036

Pharmacokinetic Comparisons of Two Donepezil Formulations

Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of Donepezil Between Two Donepezil Products, Aricept® Tablet and Neuropezil ODT, in Healthy Subjects

Sponsor: Chong Kun Dang Pharmaceutical Corp.

Conditions Alzheimer Disease

Interventions Donepezil, 10 mg tablet Donepezil, ODT 10 mg

Updated 5 times since 2017 Last updated: Feb 15, 2011 Started: Jan 31, 2008 Primary completion: Mar 31, 2008 Completion: May 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Alzheimer Disease, this trial is completed. The trial is conducted by Chong Kun Dang Pharmaceutical Corp. and has accumulated 5 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2017 — Jan 2021 [monthly]

Completed PHASE1

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chong Kun Dang Pharmaceutical Corp.
Korea University Anam Hospital

Data source: Korea University Anam Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea